KRAS G12 isoforms exert influence over up-front treatments: A retrospective, multicenter, Italian analysis of the impact of first-line immune checkpoint inhibitors in an NSCLC real-life population.
Fancelli S, Caliman E, Mazzoni F, Paglialunga L, Gatta Michelet MR, Lavacchi D, Berardi R, Mentrasti G, Metro G, Birocchi I, Delmonte A, Priano I, Comin CE, Castiglione F, Bartoli C, Voltolini L, Pillozzi S, Antonuzzo L.
Fancelli S, et al. Among authors: gatta michelet mr.
Front Oncol. 2022 Nov 14;12:968064. doi: 10.3389/fonc.2022.968064. eCollection 2022.
Front Oncol. 2022.
PMID: 36452502
Free PMC article.